Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025 (Specific date: November 20, 2025)
Context: This filing incorporates by reference a press release regarding a regulatory milestone for the company's product candidate, CF602.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose a specific corporate event and does not contain financial statements or performance data.
Material Changes
Regulatory Milestone: Can-Fite Biopharma Ltd. announced that its erectile dysfunction treatment, CF602, received a Notice of Patent Allowance in Brazil.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the patent allowance but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this Form 6-K.
Unusual Items: None reported in this specific filing text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the scope and duration of the Brazilian patent allowance.
- Confirm the commercial implications of the patent allowance for CF602 in the Brazilian market.
- Review subsequent filings for any financial impact or updated commercialization timelines related to this milestone.